News Title

Innovestor has launched a new Life Science & Health fund focusing on early-stage opportunities in the Nordic and Baltic countries - the first fund in Finland in over ten years that focuses solely on life sciences. Pekka Simula and Petri Laine, partners in the fund, highlight how the new fund aims to support the commercialization of innovation.

Innovestor Ventures is a member of the International Venture Club, and an active part of Tech Tour events and initiatives, among which the upcoming Healthtech Investment Forum, hosted by Business Finland and taking place on 8-10 March online.

Innovestor has launched a new Life Science & Health fund focusing on early-stage opportunities in the Nordic and Baltic countries - the first in Finland in over ten years that focuses solely on life sciences. The fund has completed a first closing of € 60 million and aims to increase its capital to 90-120 million euros within 12 months. State-backed Tesi (Finnish Industry Investment) acts as anchor investor in the fund.

Innovestor is a member of the International Venture Club, and an active part of Tech Tour events and initiatives, among which the upcoming Healthtech Investment Forum, hosted by Business Finland and taking place on 8-10 March online.

Pekka Simula, partner of the fund, says: “Through university cooperation, we are able to screen for innovations that have the potential to reach unicorn level. We aim to invest in about 20 companies, half of which are co-founded by us, and in addition to capital, we will bring them industry expertise. Our goal is for investors to get their money back at least 2.5 times”.

Supporting the Life Science fund team with his twenty years of venture capital experience is also Innovestor Ventures partner Petri Laine.

“Launching this fund is a result of hard work over a long period of time. An important starting point for us was that drug development and new health technologies are underfunded in Finland and in the neighbouring countries. At the same time, this region has world-leading innovation capacity and scientific know-how both from life sciences and digital healthcare solutions field. There is a great demand for this fund in the market and it opens new opportunities also for private investors. Innovestor’s previous investments in life sciences and healthcare technology companies prove that the return target for the fund is realistic.” Laine says.